Browse studies

Find your next paid study

10 recruiting studies matching your filters

A Phase 2A, Open-Label Single Arm Multicenter Exploratory Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Doses of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH).

This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial L…

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension, Interstitial Lung Disease

Estimated

~$75 – $2,800

Actual pay is set by the research site.

AllRock Bio, Inc.NCT07175038

Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.

The goal of this study is to learn more about how sotatercept works and if it helps the lung arteries become healthier. Sotatercept will be associated with the…

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Franz Rischard, DONCT07487441

Phase 1

Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with P…

Pulmonary Arterial Hypertension (PAH)

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Joseph C. WuNCT06872112

Phase 1

A Phase 1 Single-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ZMA001 in Healthy Subjects

Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more…

Pulmonary Arterial Hypertension PAH

Estimated

~$500 – $6,750

Actual pay is set by the research site.

National Heart, Lung, and Blood Institute (NHLBI)NCT05967299

Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults With Pulmonary Arterial Hypertension

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of th…

Pulmonary Arterial Hypertension (PAH)

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT07318597

Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences o…

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionScleroderma Associated Pulmonary Arterial Hypertension+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Vanderbilt University Medical CenterNCT01884051

Phase 4

An Open-label Study to Evaluate the Safety and Tolerability of LIQ861 in Participants With WHO Group 1 PAH Transitioning From Oral Selexipag to Inhaled Treprostinil

This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) wh…

Pulmonary Arterial Hypertension (PAH)

Estimated

~$25 – $1,400

Actual pay is set by the research site.

Liquidia Technologies, Inc.NCT07759804

Phase 2

A Phase II, Randomized, Double-Blind, Safety and Efficacy Study of Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus …

Pulmonary Arterial Hypertension (PAH)

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Stanford UniversityNCT07601295

Rutgers University Study of the Genetics of Pulmonary Hypertension

The goal of this observational study is to learn more about how genes impact the risk of pulmonary hypertension. Anyone 18 or older living in the US is eligibl…

Pulmonary HypertensionPulmonary Arterial HypertensionPulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)+5 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Rutgers, The State University of New JerseyNCT07217522

Phase 3

Remotely-Monitored Exercise to Enhance Functional Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Initiating Sotatercept Therapy: A Single-site Feasibility Study

Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention p…

Pulmonary Arterial Hypertension (PAH)Exercise Therapy

Estimated

~$50 – $1,500

Actual pay is set by the research site.

University of WashingtonNCT06941441